T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses
Journal of Clinical Investigation · 16.03.2026 · 136 (6)
DOI: 10.1172/jci195668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.03.2026. Verfasst von Cassandra Gilmour und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Hematology & Oncology Research. Hauptthemen laut MEDLINE: CTLA-4 Antigen, CD8-Positive T-Lymphocytes, B7 Antigens, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Cancer Institute, American Cancer Society.
Abstract (Originalsprache)
V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint protein that impairs antitumor T cell responses. While broadly expressed on myeloid cells and T cells, the specific contribution of T cell–intrinsic VISTA to antitumor immunity remains undefined. This study investigated the phenotypic and functional consequences of T cell–specific VISTA deletion in tumor-specific CD8 + T cells. Single-cell transcriptomic analysis, TCR repertoire profiling, and flow cytometry revealed that loss of T cell–intrinsic VISTA enhanced early priming and short-term expansion of CD8 + T cells, yet this initial advantage failed to confer durable tumor control. Persistent dysfunction in VISTA-deficient T cells was in part driven by trans -VISTA on myeloid cells, while CTLA-4 upregulation further constrained T cell responses. T cell–intrinsic VISTA deficiency cooperated with CTLA-4 blockade to improve T cell survival and broaden TCR repertoire diversity, resulting in more robust tumor regression than CTLA-4 inhibition alone. A transcriptional signature enriched in VISTA-deficient cytotoxic T cells correlated with favorable outcomes in cancer patients treated with existing immune checkpoint inhibitors. These findings collectively define T cell–intrinsic mechanisms by which VISTA enforces T cell dysfunction and underscore its potential as both a therapeutic target and a biomarker of resistance to current immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Hematology & Oncology Research.
- Center for Immunotherapy & Precision Immuno-Oncology.
- Breast Center, Integrated Surgical Institute, and.
- Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Microbiology and Immunology and.
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Förderung
- NIAID NIH HHS
- National Cancer Institute
- American Cancer Society
- U.S. Department of Defense CDMRP
- Department of Defense CDMRP
Zitieren
APA
Gilmour, C., DeLaney, E., Parthasarathy, P. B., Roy, D., Ta, H. M., Zakeri, A., Elguera Grandez, P., Patnaik, S., Zhang, K., Juric, I., Rangan, R., Al-Hilli, Z., Tufaro, A., Min, B., Weinberg, S. E., Chan, T. A., Silver, N. L., Avril, S., Alban, T., & Wang, L. L. (2026). T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses. Journal of Clinical Investigation, 136(6). https://doi.org/10.1172/jci195668
Vancouver
Gilmour C, DeLaney E, Parthasarathy PB, Roy D, Ta HM, Zakeri A, et al. T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses. Journal of Clinical Investigation. 2026;136(6). doi:10.1172/jci195668
BibTeX
@article{Gilmour2026,
author = {Gilmour, Cassandra and DeLaney, Elizabeth and Parthasarathy, Prerana B and Roy, Dia and Ta, Hieu M and Zakeri, Amin and Elguera Grandez, Paolo and Patnaik, Sachin and Zhang, Keman and Juric, Ivan and Rangan, Rahul and Al-Hilli, Zahraa and Tufaro, Anthony and Min, Booki and Weinberg, Samuel E and Chan, Timothy A and Silver, Natalie L and Avril, Stefanie and Alban, Tyler and Wang, Li Lily},
title = {T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {6},
doi = {10.1172/jci195668}
}
EUVIMED